Skip to Content

GW Pharmaceuticals plc

Merger

  • Date:
  • 2/3/2021
  • Company Name:
  • GW Pharmaceuticals plc
  • Stock Symbol:
  • GWPH
  • Company Name - Buyer:
  • Jazz Pharmaceuticals plc
  • Stock Symbol - Buyer:
  • JAZZ
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 2/3/2021

Case Finder

Locate any case using the tools below.

NEW YORK, February 3, 2021 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of GW Pharmaceuticals plc (NASDAQ: GWPH) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Jazz Pharmaceuticals plc (NASDAQ: JAZZ).

On February 3, 2021, GW announced that it had signed an agreement to be acquired by Jazz for approximately $7.2 billion.  Pursuant to the merger agreement, GW stockholders will receive $200 in cash and $20 worth of Jazz common stock for each share of GW common stock owned.  The deal is scheduled to close in the second quarter of 2021.

Bragar Eagel & Squire is concerned that GW’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.  Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for GW’s stockholders.
 
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in GW Pharmaceuticals plc. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: